These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Commentary: can we talk? About Food and Drug Regulation and the First Amendment. Cohen MN Food Drug Law J; 2003; 58(4):741-56. PubMed ID: 15027458 [No Abstract] [Full Text] [Related]
24. The emerging effects of the Drug Price Competition and Patent Term Restoration Act of 1984. Lewis RA J Contemp Health Law Policy; 1992; 8():361-78. PubMed ID: 10118987 [No Abstract] [Full Text] [Related]
25. A precarious balancing act--the role of the FDA as protector of public health and industry wealth. McCabe AR Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844 [No Abstract] [Full Text] [Related]
26. Market exclusivity after a prescription to nonprescription drug switch: striking the right balance between innovation and competition. Kraushaar KJ Food Drug Law J; 1999; 54(2):243-4. PubMed ID: 11758581 [No Abstract] [Full Text] [Related]
27. Raising the bar. Barcoding has the potential to dramatically reduce medication errors. Goth G Healthc Inform; 2006 Apr; 23(4):38-41. PubMed ID: 16676641 [No Abstract] [Full Text] [Related]
28. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry. Srivastava D Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015 [No Abstract] [Full Text] [Related]
29. Legal Liability of Generic vs Brand Drug Manufacturers for Inadequate Product Labels. Boumil MM; Curfman G JAMA; 2018 Aug; 320(6):547-548. PubMed ID: 30039167 [No Abstract] [Full Text] [Related]
30. FDA's regulation of prescription drug labeling: a role for implied preemption. Kendrick LC Food Drug Law J; 2007; 62(1):227-47. PubMed ID: 17444031 [No Abstract] [Full Text] [Related]
31. Pharmaceutical patent settlements: the antitrust risks. Balto DA Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464 [No Abstract] [Full Text] [Related]
32. Names in vain. Vazquez E; Whitfield L Posit Aware; 1997; 8(6):13. PubMed ID: 11364853 [TBL] [Abstract][Full Text] [Related]
33. Best buy drugs: many common generics beat brand names. Consum Rep; 2011 Mar; 76(3):24-7. PubMed ID: 21434454 [No Abstract] [Full Text] [Related]
34. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering. Paine CS Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807 [No Abstract] [Full Text] [Related]
35. Drug marketing exclusivity under United States and European Union law. Junod V Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347 [No Abstract] [Full Text] [Related]
36. America's drug problem. Philpott S Hastings Cent Rep; 2012; 42(4):9-10. PubMed ID: 22777971 [No Abstract] [Full Text] [Related]
37. AstraZeneca takes legal action to delay generic quietiapine in US. Hawkes N BMJ; 2012 Mar; 344():e2099. PubMed ID: 22422864 [No Abstract] [Full Text] [Related]
38. Pros and cons of off-label promotion investigations and prosecutions. Loucks MK Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041 [No Abstract] [Full Text] [Related]
39. Prescription for fairness: a new approach to tort liability of brand-name and generic drug manufacturers. Rostron A Duke Law J; 2011 Feb; 60(5):1123-91. PubMed ID: 21365961 [TBL] [Abstract][Full Text] [Related]